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Abstract. Podoplanin (PDPN) is a well established lymphatic 
endothelial marker and has frequently been observed in cancer 
cells at the edge of cancer masses. Previous studies investigating 
the association between PDPN expression and patient prognosis 
have had contradictory results. In the present study, it was 
hypothesized that the different locations of PDPN-positive cells 
may explain these varying results. The present study aimed to 
focus on PDPN expression at the edge of esophageal cancer 
cell nests. In order to analyze the clinical significance of this 
PDPN expression, immunohistochemistry was performed using 
esophageal cancer tissue microarrays. PDPN expression at the 
edge of the cancer cell nest was found to be significantly associ-
ated with invasion (P<0.05) and poor prognosis (P<0.001) in 
patients with cancer. To further investigate the role of PDPN 
expression in cancer cells, the PDPN gene was cloned and 
transfected into esophageal squamous cell carcinoma (ESCC) 
cell lines. PDPN expression was also knocked down using small 
interfering RNA. PDPN-positive cancer cells were found to 
exhibit invasion characteristics. Thus, PDPN expression at the 
edge of a cancer cell nest may indicate invasion and represent a 
poor prognostic factor for ESCCs.
Introduction
The mucin-type transmembrane glycoprotein podoplanin 
(PDPN) is a specific marker for lymphatic endothelial 
cells (1-5) and is frequently used to detect lymphatic numbers 
in various cancer tissues, including colon and breast 
cancer (6-17). However, PDPN is also present in normal 
follicles and cancer-associated stromal cells (18,19).
PDPN expression is associated with tumor invasion, 
metastasis and poor prognosis in cancer cells (8,15,20,21). 
However, it has also been reported that PDPN inhibits cancer 
cell invasion (22-25). Furthermore, a recent study found 
that PDPN-positive lymphatic vessel invasion is not a poor 
prognostic factor in stage I lung adenocarcinoma (26). In the 
present study, it was hypothesized that the different locations 
in which PDPN-positive expression is observed, may explain 
these contradictory results. In order to determine the func-
tion of PDPN at the edge of cancer cell nests, cancer cells 
expressing PDPN in these specific locations were investigated. 
Immunohistochemistry was performed using esophageal 
squamous cell carcinoma (ESCC) tissue microarrays (TMAs; 
234 tissues) in order to verify the clinical significance of PDPN 
expression. Furthermore, the effect of PDPN overexpression 
and knock down was investigated in cancer cells. PDPN 
expression was found to be associated with ESCC cancer cell 
invasion; however, further investigation is required.
Materials and methods
Clinical samples and cell lines. A total of 234 informative 
esophageal cancer tissues and 71 non-cancerous esophageal 
tissues collected between January 2003 and December 2007 
were obtained from the archives of the Linzhou People's 
Hospital (Linzhou, China). All samples were used to produce 
the TMA sections. The present study was approved by the 
Committee for the Ethical Review of Research Involving 
Human Subjects at Zhengzhou University (Zhengzhou, China) 
and Sun Yat-Sen University (Guangzhou, China). The clinical 
and pathological information from the patients with ESCC was 
partially complete. Mean patient age was 60.3 years at the time 
of surgery. Tumor stage assessment was classified according to 
the World Health Organization grading criteria and the tumor, 
nodes and metastasis (TNM) stage was classified according to 
the sixth version of the Union for International Cancer Control 
TNM classification criteria.
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Nine lung cancer cell lines were authenticated by testing 
for mycoplasma contamination using Mycoalert™ (Lonza 
Group, Basel, Switzerland) and through analyzing cell 
morphology. The HKESC1, EC18 and EC109 lung cancer cell 
lines were provided by Professor Tsao and Professor Srivastava 
(University of Hong Kong, Hong Kong, China) and the 
KYSE30, KYSE140, KYSE180, KYSE410, KYSE510 and 
KYSE520 lung cancer cell lines were obtained from DSMZ 
(Braunschweig, Germany).
Immunohistochemical analysis of TMAs. The sections were 
deparaffinized according to routine pathological techniques. 
Antigen retrieval was performed by boiling the specimens for 
15 min in EDTA solution, then allowing the samples to cool to 
room temperature. Sections were washed with phosphate-buff-
ered saline (PBS), followed by incubation with anti-human 
PDPN monoclonal antibodies (Dako UK Ltd, Ely, UK) diluted 
1:100. The EnVision™ detection system (Dako, Kyoto, Japan) 
was used according to the manufacturer's instructions.
Scoring PDPN‑positive cells at the edge of the cancer cell 
nest. In the present study, tumor sections from the edge of the 
cancer cell nest which exhibited positive PDPN staining were 
considered PDPN-positive cases. The immunohistochemical 
staining score only reflected the distribution of the positive 
signal at the edge of the cancer cell nest and did not include 
staining at the center of the cancer cell nest or the stromal or 
lymphatic regions. Based on the percentage of positive cells at 
the tumor edge, the samples were given a distribution score as 
follows: 0, 0-5%; 1, 6-50%; and 2, 51-100%. Furthermore, the 
staining intensity was scored a follows: 0, no signal; 1, weak; 
2, moderate; and 3, marked. The total score was calculated as 
the sum of the distribution score and the intensity score and 
ranged from 0-5. Total scores between 0 and 1 were considered 
negative, while scores between 2 and 5 were considered posi-
tive.
Plasmid vector construction. HindIII and EcoRI sites (bold) 
were incorporated into the primer sequences, which were used 
to amplify the human PDPN gene. The primer sequences were 
as follows: Forward, 5'-CCCAAGCTTGCCTCCTCGGGA 
GAGATAAAT G-3' and reverse, 5'-CCGGAATTCAACCCT 
TCAGCTCTTTAGGGCGA-3'. RNA was obtained from 
normal placenta tissue and the polymerase chain reaction 
(PCR) products were inserted into the pcDNA 3.1 plasmid 
vector (Invitrogen Life Technologies, Carlsbad, CA, USA) 
according to the manufacturer's instructions. The vector was 
then sequenced to verify the correct insert.
Quantitative (q)PCR analysis. Total RNA was extracted from 
the cultured cell lines. The qPCR primer sequences for PDPN 
were as follows: Forward, 5'-GTGTAACAGGCATTCGCA 
TCG-3' and reverse, 5'-TGTGGCGCTTGGACTTTGT-3'. 
PDPN expression was normalized to that of GAPDH and 
expressed as the fold change relative to the mean level of the 
control group.
Stable transfection and small interfering (si)RNA knockdown. 
The pcDNA 3.1 vector containing the human PDPN cDNA 
insert or the empty pcDNA 3.1 control vector were trans-
fected into a series of cell lines using Lipofectamine® 2000 
(Invitrogen Life Technologies) according to the manufacturer's 
instructions. Forty-eight hours after transfection, the culture 
medium was replaced with medium containing 450 µg/ml 
G418. Cells were then maintained in Dulbecco's modified 
Eagle's medium (DMEM) containing 10% fetal bovine serum 
(FBS) and G418 (Invitrogen Life Technologies) until the 
resistant cells had grown. Human PDPN siRNA and control 
siRNA were purchased from Shanghai Genepharma Co., 
Ltd. (Shanghai, China) and transfection was performed using 
Lipofectamine 2000.
Proliferation assay. An XTT cell proliferation assay kit (Roche, 
Basel, Switzerland) was used to determine the proliferation rates 
of a series of cancer and control cell lines. Cells were seeded at a 
density of 1x103 cells/well on 96‑well plates and cultured for five 
days (n=4 per cell line).
Invasion assay. Cell invasion was determined using a 
Transwell® system (BD Biosciences, San Jose, CA, USA) 
with an 8-µm polyethylene terephthalate membrane. The 
upper chamber was coated with Matrigel™ and seeded with 
1x105 cells in DMEM containing 2% FBS. DMEM containing 
10% FBS was added to the lower chamber. After 18 h, the 
cells were scraped from the upper side of the membrane 
using a cotton swab. Subsequent to washing with PBS, the 
cells that had migrated to the lower chamber were fixed with 
75% ethanol and stained with a 1% crystal violet solution. The 
membrane was carefully removed using a knife and mounted 
onto a glass slide using a sealing reagent. The migrated cells 
were counted in fields and the mean number of cells counted 
in five fields was used for the analysis.
Statistical analysis. SPSS 16.0 (SPSS, Inc., Chicago, IL, 
USA) was used to analyze the data, which are presented as 
the mean ± standard deviation. Fisher's exact test or the χ2 test 
were used to compare the statistical significance of the differ-
ences in PDPN expression between the ESCC TMAs. Clinical 
pathological factors, including age, gender, histological and 
pathological stages, invasion and TNM stage were considered, 
and a Log-rank test for survival was performed to compare 
the positive and negative staining results. Kaplan-Meier curves 
were plotted according to overall survival. P<0.05 was consid-
ered to indicate a statistically significant difference.
Results
PDPN is frequently expressed at the edge of ESCCs. PDPN has 
previously been reported to be a lymphatic marker expressed 
in endothelial cells. The findings of the present study are 
consistent with those of a previous study, with regard to PDPN 
expression in patients with ESCC (Fig. 1A) (27). In addition, 
PDPN was found to be expressed at the edge of the cancer 
cell nest (Fig. 1B). In order to further verify PDPN cancer 
cell expression, PDPN mRNA levels were analyzed in various 
cell lines using qPCR analysis. A total of 66.7% (6/9) of the 
ESCC cell lines were observed to express PDPN (Fig. 1C), 
with the HKESC1, EC18, KYSE140, KYSE180, KYSE510 and 
KYSE520 cell lines demonstrating PDPN expression, while 
the EC109, KYSE30 and KYSE410 cell lines did not.
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PDPN expression at the front edge of the cancer cell nest is 
associated with invasion and poor prognosis. To investigate 
the clinical significance of PDPN expression at the edge of the 
ESCC cancer cell nest, the cancer cells from 234 patients with 
informative clinical and pathological data were investigated. 
PDPN-positive cells at the edge of the tumor are indicated 
by the arrow (Fig. 2A). Kaplan-Meier analysis revealed that 
PDPN cancer cell expression was associated with poor overall 
survival (P<0.001; Fig. 2B).
To further assess the significance of PDPN expression in 
ESCC tissue, the correlation between PDPN expression at the 
edge of the cancer cell nest and pathological data was assessed 
in the patients. PDPN expression at the edge of the cancer cell 
nest was found to be positively correlated with cancer inva-
sion in ESCC tissue (Table I; P<0.05), but was not found to be 
associated with any other clinical features.
PDPN induces invasion, but does not affect growth in ESCC 
cells. In order to investigate the invasive function of PDPN 
in ESCC pathogenesis, PDPN was cloned into the pcDNA 3.1 
vector and an empty vector was used as the control. The vectors 
were stably transfected into the KYSE410 and EC109 cell lines 
and two clones were selected to avoid clone deviation. Prior 
to the functional analyses, the overexpression of PDPN was 
determined using qPCR analysis, which revealed increased 
PDPN expression in the PDPN-transfected cells (Fig. 3A). The 
effect of PDPN on tumor invasion was then assessed using a 
Transwell assay. PDPN was observed to significantly promote 
invasion in the ESCC cell lines (P<0.05; Fig. 3C and D).
In addition to the invasion assay, an MTT assay was 
performed to assess the growth of the KYSE410 and EC109 
cells over five days. No significant difference was found in the 
growth rate of the PDPN-transfected cells compared with the 
growth rate of the cells expressing the empty vector (P>0.05; 
Fig. 3B).
PDPN downregulation inhibits tumor invasion. To further 
analyze whether PDPN has a role in activating cell invasion, 
PDPN knockdown was performed using an antisense oligo-
nucleotide (Fig. 4A). Wound healing assays revealed that 
PDPN knockdown markedly inhibited KYSE520 cell motility 
compared with that of the control cells (Fig. 4B). To assess 
the invasive capacity of the PDPN knockdown cell lines, a 
cell invasion assay was performed using a coated Matrigel 
Transwell system. Statistical analysis demonstrated that PDPN 
silencing significantly inhibited invasion in the tumor cells. 
Figure 1. PDPN overexpression in ESCC cell lines at the front edge of ESCC tissues. PDPN expression in (A) a lymphatic vessel and (B) at the edge of a cancer 
cell nest (magnification, x200). (C) PDPN expression was determined using quantitative polymerase chain reaction analysis in nine ESCC cell lines with 67% 
(6/9) of the cell lines found to be positive for PDPN expression. PDPN, podoplanin; ESCC, esophageal squamous cell carcinoma.
Figure 2. Clinical significance of PDPN expression at the edge of ESCCs in patient samples. (A) PDPN-positive cells at the edge of a cancer cell nest detected 
using immunohistochemisty of ESCC tissue microarrays (magnification, x100). (B) Survival analysis of patients with PDPN‑positive and‑negative cells at the 
edge of their cancer nest. PDPN expression was positive in 66.7% (156/234) of patients. Kaplan-Meier analysis revealed that the PDPN-positive patient group 
had a significantly lower overall survival compared with the PDPN‑negative group (P<0.05). PDPN, podoplanin; ESCC, esophageal squamous cell carcinoma.
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Furthermore, PDPN knockdown was found to induce a more 
static state compared with the control cells (data not shown).
Discussion
PDPN expression in lymphatic vessels may have value as a 
predictive marker of survival. However, PDPN is also expressed 
in cancer cells, cancer stromal cells and cancer cells at the edge 
of cancer cell nests. Reports regarding the clinical prognostic 
significance of PDPN expression in cancer tissues are contradic-
tory, thus further investigation is required. In the present study, 
it was hypothesized that determining the different locations of 
PDPN expression may explain the contradictory results.
A previous study by our group found that PDPN was 
expressed in lymphatic vessels, which was consistent with other 
reports (Fig. 1A) (28-30). The present study focused on PDPN 
expression at the edge of cancer cell nests as epithelial-mesen-
chymal transition is not the only invasion mechanism used 
by cancerous cells. Preliminary results revealed that PDPN 
expression at the edge of cancer cell nests was positively 
correlated with invasion and poor patient survival. These 
findings indicated that other factors may contribute to cancer 
cell invasion, as the PDPN-positive cells were invasive without 
epithelial-mesenchymal transition (22).
The present study showed that PDPN-positive cancer cells 
have functions which are associated with invasion. Recent 
reports have shown that PDPN is harmful to patients with 
ESCC (27,28). Although these studies did not focus on front 
edge cancer cells, their findings are consistent with those of the 
present study. The mechanism through which PDPN expres-
sion at the edge of a cancer cell nest contributes to cancer 
cell invasion requires further investigation. It is possible that 
these cells are induced to express PDPN through factors in the 
cancer microenvironment; however, the findings of the present 
study suggested that PDPN has a role in invasion. Tumors 
are a complex mixture of cells and extracellular matrix (31); 
therefore, the cross-talk between PDPN-positive cancer cells 
and the cancer stroma should be investigated.
Table I. Clinical signficance of PDPN expression at the front edge of the cancer cell nest in 234 primary ESCCs.
 PDPN expression, n (%)
 ------------------------------------------------------------------------------
Clinical parameter Cases (n) Positive Negative P-value
Gender    0.229
  Female 116 73 (62.9) 43 (37.1)
  Male 118 83 (70.3) 35 (29.7)
Age    0.141
  ≤60 134 85 (63.4) 49 (36.6)
  >60 100 71 (71.0) 29 (29.0)
Lymph node metastasis    0.888
  N0 135 89 (71.2) 46 (36.8)
  N1 99 67 (67.6) 32 (32.3)
TNM stage    1.00
  Early stage (I-II) 159 106 (66.7) 53 (33.3)
  Advanced stage (III-IV) 75 50 (66.7) 25 (33.3)
Tumor size (cm3)    0.166
  ≤5 29 13 (44.8) 16 (51.2)
  >5 148 87 (50.6) 61 (49.4)
Distance metastasis    0.858
  Metastasis 4 2 (50.0) 2 (50)
  No metastasis 230 154 (67.0) 76 (33.0)
Tumor differentiation    0.222
  Good (I-II) 29 19 (65.5) 10 (34.5)
  Moderate (III) 155 103 (66.5) 52 (33.5)
  Poor (IV) 48 34 (70.8) 14 (29.2)
Tumor invasion    0.013
  T1 88 50 (56.8) 38 (43.2)
  T2 146 106 (72.6) 40 (27.4)
Tumor size was measured using the following formula: 0.5 x length x (width)2. Partial data are not available for tumor size and tumor dif-
ferentiation and the statistic was based on the informative data. Invasion was defined by the results of a final pathological analysis. PDPN, 
podoplanin; ESCC, esophageal squamous cell carcinoma.
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Figure 3. PDPN activates ESCC invasion, but does not affect tumor cell growth. (A) Quantitative polymerase chain reaction analysis revealed increased 
PDPN expression in PDPN-transfected cells. (B) Cancer cell growth rate in cells transfected with PDPN compared with those transfected with an empty 
vector detected using MTT assay. Data are presented as the mean ± standard deviation of three independent experiments. (C) PDPN promoted KYSE410 
(upper panels) and EC109 (lower panels) cell migration (magnification, x400). *P<0.001. (D) Results of the invasion assay. *P<0.05. Data are presented as the 
mean ± standard deviation of three independent experiments. PDPN, podoplanin.
Figure 4. PDPN knockdown reduces tumor cell migration and invasion. (A) PDPN was silenced through transfection with siRNA. PDPN knockdown was con-
firmed using quantitative polymerase chain reaction analysis in the KYSE520 and KYSE140 cell lines. (B) Tumor cell motility was reduced following PDPN 
knockdown. Representative images of KYSE520 were captured at 0 and 48 h. (C) Cancer cell invasion was determined using a Transwell™ assay. PDPN knock-
down reduced cell migration (magnification, x400) (D) Cell invasion is expressed as the mean ± standard deviation of three independent experiments. *P<0.05. 
PDPN, podoplanin; si, small interfering.
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Future studies by our group will focus on investigating 
the invasion mechanism induced by PDPN expression. 
Understanding the role of PDPN in cancer cells will enhance 
the knowledge of cancer invasion and may ultimately 
allow researchers to diagnose pathology through targeting 
PDPN-positive cancer cells at the edge of cancer cell nests. 
However, more research is still required to achieve these goals.
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